CINECA IRIS Institutional Research Information System

INGHIRAMI, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.025
EU - Europa 5.480
AS - Asia 3.130
AF - Africa 70
SA - Sud America 31
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.915
CN - Cina 1.653
DE - Germania 839
IT - Italia 823
IE - Irlanda 693
SE - Svezia 597
SG - Singapore 569
UA - Ucraina 558
FR - Francia 523
KR - Corea 462
FI - Finlandia 431
AT - Austria 259
GB - Regno Unito 185
DK - Danimarca 176
PL - Polonia 161
VN - Vietnam 107
CA - Canada 105
JP - Giappone 96
IN - India 77
SN - Senegal 58
BE - Belgio 45
HK - Hong Kong 34
NL - Olanda 29
ES - Italia 28
AU - Australia 26
ID - Indonesia 26
CZ - Repubblica Ceca 22
GR - Grecia 22
RU - Federazione Russa 22
TW - Taiwan 22
BR - Brasile 21
CH - Svizzera 16
IR - Iran 15
BY - Bielorussia 13
TR - Turchia 11
RO - Romania 10
QA - Qatar 9
PH - Filippine 7
PK - Pakistan 7
PT - Portogallo 7
SA - Arabia Saudita 7
NO - Norvegia 6
CL - Cile 5
EG - Egitto 5
MX - Messico 5
MY - Malesia 5
RS - Serbia 5
TH - Thailandia 5
UZ - Uzbekistan 5
EU - Europa 4
MO - Macao, regione amministrativa speciale della Cina 4
HU - Ungheria 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
AR - Argentina 2
IQ - Iraq 2
LU - Lussemburgo 2
NG - Nigeria 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
IL - Israele 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
TG - Togo 1
ZA - Sudafrica 1
Totale 15.769
Salva come PNG Salva come JPEG
Città #
Beijing 1.003
Chandler 813
Dublin 691
Singapore 419
Ann Arbor 414
Villeurbanne 395
Jacksonville 354
Ashburn 317
Houston 308
Princeton 299
Santa Clara 289
Torino 254
Medford 251
Fairfield 243
Vienna 219
Columbus 210
Wilmington 193
Dearborn 179
Nyköping 167
Warsaw 158
Woodbridge 117
Redwood City 110
Boston 89
Cambridge 81
Seattle 80
San Mateo 77
Fremont 72
Guangzhou 72
Milan 72
Dong Ket 71
Pisa 70
Boardman 69
Shanghai 67
Toronto 47
Nanjing 46
Centro 45
Verona 45
New York 42
Brussels 37
Falls Church 31
Norwalk 30
Turin 30
Pune 28
Jakarta 26
Hefei 25
Tokyo 24
Chengdu 23
Lachine 23
Hangzhou 20
Mountain View 20
Philadelphia 20
Bologna 18
Kunming 18
Munich 18
Düsseldorf 17
Rome 17
Zhengzhou 17
Jinan 16
Los Angeles 16
Ottawa 15
Fuzhou 14
San Diego 14
Washington 14
Nürnberg 13
Taipei 13
Wuhan 13
Phoenix 11
Shenyang 11
Tianjin 11
Detroit 10
Hong Kong 10
Nanchang 10
Xian 10
Changsha 9
Doha 9
Grafing 9
Helsinki 9
Redmond 9
Wenzhou 9
Chicago 8
Cleveland 8
Des Moines 8
Barcelona 7
Central District 7
Modena 7
New Haven 7
Olomouc 7
Rochester 7
Birmingham 6
Changchun 6
Fountain Valley 6
Kish 6
Leiden 6
Thening 6
Austin 5
Buffalo 5
Chennai 5
Durham 5
Genova 5
Hebei 5
Totale 9.277
Salva come PNG Salva come JPEG
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 736
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. 518
Core binding factor acute myeloid leukaemia and c-KIT mutations 415
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 362
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. 346
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. 253
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 252
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 236
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 231
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 225
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling 212
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK positive anaplastic large cell lymphoma. 185
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 184
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. 180
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 175
The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank 170
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas 166
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 163
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials 160
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 143
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 142
PDX-MI: Minimal information for patient-derived tumor xenograft models 141
The genetics of nodal marginal zone lymphoma 137
Core binding factor acute myeloid leukemia and c-kit mutations 129
Anaplastic lymphoma kinase in human cancer 126
The heterogeneous landscape of ALK negative ALCL 120
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 119
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL 118
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 117
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 114
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 113
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas 110
Anaplastic large-cell lymphoma 107
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 107
Analysis of the activating Kras mutations in advanced colorectal tumors: a three-year diagnostic experience 106
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 103
Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits 101
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 98
CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation 97
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma 96
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death 94
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination 93
Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination 91
Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma 89
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas 88
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 88
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 86
Unveiling the pathogenetic role of Stat3 in human lymphoma 86
Molecular anatomy of peripheral T cell lymphomas 85
Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation 82
Anaplastic lymphoma kinase: an oncogene for tumor vaccination 81
Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses 80
Dendritic cells transfected with DNA encoding ErbB2 rat/human chimeric plasmids are able to activate in vitro a specific T cell response in ErbB2+ cancer patients 80
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes 79
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA 78
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. 78
The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells 78
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. 78
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation 77
Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers 77
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. 76
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. 76
Anaplastic lymphoma Kinase: molecular mechanisms of lymphoid transformation 75
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 75
Development of a consensus IgH quantitative assay for the detection of minimal residual disease in Chronic Lymphocytic Leukemia using 3’-minor groove binder probes. 74
Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity 73
Anti-Hu-associated peripheral nerve and muscle microvasculitis. 73
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 73
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 73
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target 71
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 71
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase 71
Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. 70
Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred? 69
Transposable elements: The enemies within 69
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 68
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression 68
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib 67
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas 67
The anaplastic lymphoma kinase in the pathogenesis of cancer 67
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. 67
ALK protein tyrosine kinase, cells and methods embodying and using same 66
Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells 66
Induction of germinal centers by MMTV encoded superantigen on B cells. 65
Gene Expression Profiling Uncovers Molecular Classifiers for theRecognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms 64
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. 64
Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells 63
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. 62
Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas 62
Network-based inference of tumorogenic culprits in human T-cell lymphoproliferative disorders 61
N- and K-ras oncogenes in plasma cell dyscrasias. 61
Mutational activation of N-and K-RAS oncogenes in plasma cell dyscrasia. 58
Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders 58
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. 58
Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. 57
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. 56
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. 56
Gene expression profiling uncovers molecular classifiers for the recognition of Anaplastic Large Cell Lymphoma within Peripheral T-cell neoplasms 55
N- and K-ras oncogenes in plasma cell dyscrasias. 55
Identification and validation of the anaplastic large cell lymphoma signature 54
Totale 11.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.888
article - articoli 0
book - libri 0
conference - conferenze 5.413
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.301
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.430 0 0 0 0 0 336 295 146 194 188 165 106
2020/20211.641 183 84 132 100 176 66 183 55 201 167 110 184
2021/20222.179 92 91 100 194 87 154 182 110 71 202 377 519
2022/20232.658 401 208 44 252 221 713 214 130 241 69 88 77
2023/20241.220 154 203 61 39 84 200 40 72 15 57 76 219
2024/20251.378 42 180 121 358 659 18 0 0 0 0 0 0
Totale 16.380